RxDoctor Payments Data

Ma Belinda Lu, MD

Internal Medicine · Winchester, TNNPI 1578756912

Payments from drug & device makers

$2,136in general payments, 2019–2025

Across 99 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$737
  • Smith+Nephew$345
  • Paratek Pharmaceuticals, Inc.$302
  • Abbott$174
  • AbbVie$123
  • Solventum Corporation$75
  • plus $380 from 13 others

What the payments were for

  • Speaking & faculty fees$864%
  • Food & beverage$2,05096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.16$737
Smith+Nephew26$345
Paratek Pharmaceuticals, Inc.27$302
Abbott2$174
AbbVie(2 entities)7$123
Solventum Corporation4$75
KCI USA, Inc.3$55
Molnlycke Health Care US, LLC2$51
OVIK Health, LLC1$45
Progenacare Global, LLC1$43
Reapplix Inc.2$32
Convatec Inc.1$28
Hartmann USA, Inc.1$24
Melinta Therapeutics, LLC1$21
Sanara Medtech Inc.1$20
Mckesson Patient Care Solutions Inc.1$20
Integra Lifesciences Corporation1$15
Kerecis Limited1$14
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,136 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$93,745
Medicare patients
174
Services billed
1,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CeftriaxoneCeftriaxone Sodium21$10,241
SantylCollagenase Clostridium Hist.14$5,746
Linezolid17$1,333
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$525
Levofloxacin62$517
Doxycycline Hyclate44$300
Gentamicin Sulfate12$267
Ciprofloxacin Hcl14$87
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$86
Triamcinolone Acetonide11$50
Fluconazole14$34
Furosemide11$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$345$5,74614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Winchester

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →